Stay updated with breaking news from லாச்சேன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Outlook Traveller SIGN IN WITH GOOGLE There s lots to do around Ravangla, Photo Credit: Shutterstock Home > Explore > Story > Holy Caves and Hot Springs: What To Do Around Ravangla Ravangla in South Sikkim is dotted with pretty villages surrounded by alpine trees, and jaw-dropping views of the Himalayas. 09 Min Read The sleepy town of Ravangla is ideal for a break in the Himalayas. Located between Maenam and Tedong Hill at an altitude of 7000ft, this is the place to come to if you are looking for some quiet time. Khangchendzonga, Pandim, Siniolchu, and Kabru are just some of the majestic Himalayan peaks that are visible from various points. ....
Outlook Traveller SIGN IN WITH GOOGLE The landscape around the hamlet, Photo Credit: Karan Kaushik Home > Explore > Story > Tracing Guru Nanak s Steps in Lachen Scenic Chungthang was anointed as changi than , or beautiful place by the founder of Sikhism, on his journey to Tibet. The Gurudwara Guru Nanak Lama Sahib stands here today 08 Min Read Chungthang, a little hamlet located at the confluence of Lachen and Lachung in North Sikkim holds immense historical and religious significance. Famous for the Gurudwara Guru Nanak Lama Sahib, the scenic town of Chungthang is a must-visit for everyone travelling in these parts.
The Gurudwara is located in the bustling Chungthang Bazar. Before heading here, stop at the Chungthang Dam View Point to enjoy panoramic views of the town and the Chungthang Dam built on the Teesta river coming from Lachen and Lachung. The golden domes of the Gurudwara set against a picturesque backdrop of souring peaks, ....
New USP 922 Water Activity Method for the Pharmaceutical Industry Novasina water activity meters can be matched to the official USP water activity method, USP 922 April 9, 2021 LACHEN, SWITZERLAND April 6, 2021 Life Science Newswire The United States Pharmacopeia (USP) will release the new method USP 922 in May 2021, which will outline recommendations for the determination of water activity. It includes a brief theoretical background explanation, the best practices for water activity measurement and an overview of potential applications for water activity in pharmaceutical products. USP 1112 , the first informational chapter on water activity published by USP back in 2006, did not provide guidance or instructions on best practices for water activity measurement. The new method USP 922 now addresses these limitations and highlights the potential of water activity measurement in the pharmaceutical industry. ....
Share this article Share this article LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq ®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq ....
22 febbraio 2021 17:11 Fonte: Adnkronos #chimica-e-farmacia - LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®. The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 1 ....